Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan
Journal
Journal of Comparative Effectiveness Research
Journal Volume
8
Journal Issue
2
Pages
73-79
Date Issued
2019
Author(s)
Hsu T.-C.
Abstract
Aim: Oral uracil-tegafur/leucovorin (UFT/LV) and intravenous 5-fluorouracil (FU)/LV are common adjuvant therapies for Stages II and III colorectal cancer. This study aims to determine the most cost-effective treatment alternative between UFT/LV and 5-FU/LV in Stages II and III colorectal cancer from Taiwan's National Health Insurance perspective. Patients & methods: The costs were referenced directly from the National Health Insurance reimbursement price. Chemotherapy regimen considered for the cost analysis calculation was adapted from NSABP-C-06 study, and, a time saving calculation was also included. In addition, we compare the treatment outcome. Result: A total cost saving of US$3620.80-$3709.16 per patient per treatment was achieved with the UFT/LV treatment. UFT/LV provides the comparable outcome to 5-FU/LV. Conclusion: UFT/LV was the more cost-effective treatment as adjuvant chemotherapy. ? 2019 2018 Future Medicine Ltd.
Subjects
chemotherapy; cost-effective; NHI reimbursement price; oral; stage II and III colorectal cancer; UFT; uracil-tegafur
SDGs
Other Subjects
fluorouracil; folinic acid; UFT; ufur; antineoplastic agent; antineoplastic antimetabolite; fluorouracil; folinic acid; tegafur; uracil; vitamin B complex; Article; cancer chemotherapy; cancer staging; clinical article; colorectal cancer; controlled study; cost benefit analysis; cost control; cost effectiveness analysis; disease free survival; drug cost; hospital admission; human; multiple cycle treatment; overall survival; priority journal; Taiwan; treatment outcome; adjuvant chemotherapy; adult; aged; colorectal tumor; economics; female; health care cost; male; middle aged; multimodality cancer therapy; oral drug administration; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Cost Control; Female; Fluorouracil; Health Care Costs; Humans; Leucovorin; Male; Middle Aged; Taiwan; Tegafur; Treatment Outcome; Uracil; Vitamin B Complex
Type
journal article